Ind-Swift Laboratories (INDSWFTLAB) Fundamentals 2026 — P/E 44.3x, Revenue Analysis | SniperIQ
Ind-Swift Laboratories (INDSWFTLAB) is a India-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₹2,027 Crore, trading at ₹233.07 on the NSE. This SniperIQ fundamentals page covers Ind-Swift Laboratories's valuation (P/E 44.3x, P/B 1.4x), profitability (net margin 6.6%), revenue (₹641 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Ind-Swift Laboratories's market cap?
Ind-Swift Laboratories (INDSWFTLAB) has a market capitalization of approximately ₹2,027 Crore, trading at ₹233.07 on the NSE. Market cap moves with the live share price.
What is Ind-Swift Laboratories's P/E ratio?
Ind-Swift Laboratories's trailing twelve-month P/E ratio is 44.3x, with a price-to-book (P/B) of 1.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Ind-Swift Laboratories?
Ind-Swift Laboratories runs a net profit margin of 6.6%, a gross margin of 41.1%, and an operating margin of 7.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Ind-Swift Laboratories generate?
Ind-Swift Laboratories reported revenue of ₹641 Crore for fiscal year 2026, with net income of ₹41 Crore and earnings per share (EPS) of 4.95. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Ind-Swift Laboratories pay a dividend?
Ind-Swift Laboratories does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Ind-Swift Laboratories financially healthy?
Ind-Swift Laboratories carries a debt-to-equity ratio of 0.01x and a current ratio of 3.80x, with a market beta of 0.58. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Ind-Swift Laboratories a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Ind-Swift Laboratories (INDSWFTLAB) the key facts are: market cap ₹2,027 Crore, P/E 44.3x, revenue ₹641 Crore, 52-week range 87.15-248.45. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Ind-Swift Laboratories's full fundamentals live
Get Ind-Swift Laboratories's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.